Lincomycin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
'''''For patient information, click <u>[[XXXXX (patient information)|here]]</u>'''''. | |||
Revision as of 20:50, 9 January 2014
| Lincomycin |
|---|
| LINCOCIN®, LINCOMED®, LINCOMIX® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
| Compatiblity |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here.
Overview
Lincomycin is a lincosamide antibiotic that comes from the actinomyces Streptomyces lincolnensis. It has been structurally modified to its more commonly known 7-chloro-7-deoxy derivative, Clindamycin.
Category
Lincosamide.
US Brand Names
LINCOCIN®, LINCOMED®, LINCOMIX®.
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages